Biogen Idec initiated with "neutral weight" | newratings.com
Thursday, December 28, 2006 1:40:04 AM ET
Prudential Financial
NEW YORK, December 28 (newratings.com) - Analyst Jason Zhang of Prudential Financial initiates coverage of Biogen Idec Inc (BIIB.NAS) with a "neutral weight" rating. The target price is set to $53.
In a research note published yesterday, the analyst mentions that robust sales of Avonex and Rituxan are expected to support the company’s share price. Tysabri may reach blockbuster status by 2009, the analyst says. While Biogen Idec is likely to witness pressure on Avonex’s market share due to competition from other MS drugs, Rituxan has limited scope for growth, given that the drug has saturated the NHL/CLL market, Prudential Financial adds.
http://www.newratings.com/analyst_news/article_1448747.html
Thursday, December 28, 2006 1:40:04 AM ET
Prudential Financial
NEW YORK, December 28 (newratings.com) - Analyst Jason Zhang of Prudential Financial initiates coverage of Biogen Idec Inc (BIIB.NAS) with a "neutral weight" rating. The target price is set to $53.
In a research note published yesterday, the analyst mentions that robust sales of Avonex and Rituxan are expected to support the company’s share price. Tysabri may reach blockbuster status by 2009, the analyst says. While Biogen Idec is likely to witness pressure on Avonex’s market share due to competition from other MS drugs, Rituxan has limited scope for growth, given that the drug has saturated the NHL/CLL market, Prudential Financial adds.
http://www.newratings.com/analyst_news/article_1448747.html
posted by Bill at 1:09 AM
0 Comments:
Post a Comment
<< Home